Karyopharm reports fourth quarter and full year 2022 financial results and highlights recent company progress

-- total revenue of $157.1 million and u.s. xpovio® (selinexor) net product revenue of $120.4 million for full year 2022, meeting company's guidance -- -- updated results from the phase 1 study of selinexor in combination with ruxolitinib in patients with treatment-naÏve myelofibrosis and interim data from the phase 2 study evaluating eltanexor in relapsed/refractory myelodysplastic neoplasms expected in 1h 2023 -- -- company provides full year 2023 total revenue guidance of $160 million to $175 million, including u.s. xpovio net product revenue guidance of $125 million to $140 million ; cash runway to late 2025 --  -- conference call scheduled for today at 8:00 a.m. et-- newton, mass.
KPTI Ratings Summary
KPTI Quant Ranking